These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36642992)

  • 1. Improved Medication Adherence with the Use of Extended-Release Tacrolimus in Liver Transplant Recipients: A Pilot Randomized Controlled Trial.
    Verma M; Zaki R; Sadeh J; Knorr JP; Gallagher M; Parsikia A; Navarro V
    J Transplant; 2023; 2023():7915781. PubMed ID: 36642992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the Pill Burden: Immunosuppressant Adherence and Safety after Conversion from a Twice-Daily (IR-Tac) to a Novel Once-Daily (LCP-Tac) Tacrolimus Formulation in 161 Liver Transplant Patients.
    Maurer MM; Ibach M; Plewe J; Winter A; Ritschl P; Globke B; Öllinger R; Lurje G; Schöning W; Pratschke J; Eurich D
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of once-daily ER-Tac on trough concentration variability in a stable AYA renal transplant recipient cohort.
    Chandran MM; Blanchette E; Goebel J; Bock M
    Pediatr Transplant; 2021 Sep; 25(6):e14036. PubMed ID: 34003550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients.
    Pape L; Heidotting N; Ahlenstiel T
    Int J Nephrol; 2011; 2011():126251. PubMed ID: 21647310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.
    Vadcharavivad S; Saengram W; Phupradit A; Poolsup N; Chancharoenthana W
    Drugs; 2019 Dec; 79(18):1947-1962. PubMed ID: 31713065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland.
    Bonani M; Balaphas A; Bedino G; Bühler L; Dutkowski P; Fausch K; Gluderer S; Graf N; Hirt-Minkowski P; Müllhaupt B; Schönholzer C; Schulz MM; Venzin R; Wüthrich RP
    Swiss Med Wkly; 2021 Feb; 151():w20453. PubMed ID: 33638353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial.
    Plischke M; Riegersperger M; Dunkler D; Heinze G; Kikić Ž; Winkelmayer WC; Sunder-Plassmann G
    PLoS One; 2015; 10(8):e0135674. PubMed ID: 26270340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients.
    Ruangkanchanasetr P; Sanohdontree N; Supaporn T; Sathavarodom N; Satirapoj B
    Ann Transplant; 2016 Dec; 21():765-774. PubMed ID: 27980321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
    Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
    Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.
    Zaltzman JS; Lai V; Schulz MZ; Moon KH; Cherney DZ
    Transpl Int; 2014 Dec; 27(12):1294-302. PubMed ID: 25160518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
    Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
    Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation.
    Beckebaum S; Iacob S; Sweid D; Sotiropoulos GC; Saner F; Kaiser G; Radtke A; Klein CG; Erim Y; de Geest S; Paul A; Gerken G; Cicinnati VR
    Transpl Int; 2011 Jul; 24(7):666-75. PubMed ID: 21466596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan.
    Uemoto S; Abe R; Horike H; So M
    Transplant Proc; 2014 Apr; 46(3):749-53. PubMed ID: 24767340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age and sex determine conversion from immediate-release to extended-release tacrolimus in a multi-center cohort of Canadian pediatric renal transplant recipients.
    Lang S; Sharma A; Foster B; Gibson IW; Ho J; Nickerson P; Wishart D; Blydt-Hansen T
    Pediatr Transplant; 2021 Aug; 25(5):e13959. PubMed ID: 33368914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report.
    Füessl L; Kreuzer L; Nierychlewski K; Seibt T; Stangl MJ; Koliogiannis D; Meiser B; Schwarz M; Fischereder M; Kemmner S
    Front Med (Lausanne); 2024; 11():1336035. PubMed ID: 38988355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.